Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Mar 3, 2022
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Phio Pharmaceuticals Corp.
| -8.95K |
$0.82 | -$7,351.23 | -4.05% | 212.33K |
Mar 1
| |||||||
Phio Pharmaceuticals Corp.
| 126K |
—
|
—
| +132.24% | 221.28K |
Feb 15
| |||||||
Phio Pharmaceuticals Corp.
| 6K |
$1.63 | $9,780.00 | +6.72% | 95.28K |
Aug 16
| |||||||
Phio Pharmaceuticals Corp.
| 1.95K |
$2.56 | $4,999.68 | +2.24% | 89.28K |
Mar 4
| |||||||
Phio Pharmaceuticals Corp.
| 70.95K |
$3.03 | $7,575.00 | +433.20% | 87.33K |
Mar 1 - Mar 3
| |||||||
Phio Pharmaceuticals Corp.
| 2K |
$2.50 | $5,000.00 | +13.91% | 16.38K |
Aug 19
| |||||||
Phio Pharmaceuticals Corp.
| -673.00 |
$2.93 | -$1,971.89 | -4.40% | 14.63K |
Mar 1
| |||||||
Phio Pharmaceuticals Corp.
| 350K |
$0.10 | $35,000.00 | +73.25% | 827.82K |
Nov 18
| |||||||
Phio Pharmaceuticals Corp.
| -1.24K |
$0.40 | -$498.11 | -0.26% | 477.82K |
Aug 1
| |||||||
Phio Pharmaceuticals Corp.
| 407.7K |
—
|
—
| +571.41% | 479.05K |
Mar 1
| |||||||
Phio Pharmaceuticals Corp.
| 55K |
—
|
—
| +336.39% | 71.35K |
Feb 13
| |||||||
Rxi Pharmaceuticals Corp
| 16K |
—
|
—
| +4,571.43% | 16.35K |
Aug 1
| |||||||
Rxi Pharmaceuticals Corp
| 3.5K |
$0.62 | $2,170.00 |
∞
| 3.5K |
Jun 23
| |||||||
Rxi Pharmaceuticals Corp
|
0
|
—
|
—
|
—
|
0
|
Apr 24
| |||||||
Rxi Pharmaceuticals Corp
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||